REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- REGN [1]
- Listing exchanges
- Nasdaq [1]
- SEC industry
- Pharmaceutical Preparations [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- REGENERON PHARMACEUTICALS, INC. [1]
- Headquarters location
- Eastview [2]
- Business address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591 [1]
- Founded
- 1988 [2]
- Legal form
- New York Business Corporation [2]
- Incorporation jurisdiction
- New York, United States [1]
- Official website
- www.regeneron.com ↗ [2]
- Annual revenue
- USD 12,172,900,000 · reported year 2022 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US75886F1075 [2]
- CIK
- 0000872589 [1]
- SIC code
- 2834 [1]
- Country in background record
- United States [2]
Company positioning and business
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. [3]
Background text: Wikipedia contributors, Regeneron Pharmaceuticals. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Understanding company scale
Annual revenue: USD 12,172,900,000 · reported year 2022. [2]
Financial year, securities and disclosures
The SEC submissions record gives REGENERON PHARMACEUTICALS, INC. a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: REGN (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2834. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was REGENERON PHARMACEUTICALS, INC. founded?
Founded: 1988. The linked source provides the background record. [2]
Where is the headquarters of REGENERON PHARMACEUTICALS, INC.?
Headquarters location: Eastview. The linked source provides the background record. [2]
Which business sectors are recorded for REGENERON PHARMACEUTICALS, INC.?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
REGENERON PHARMACEUTICALS, INC. relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — REGENERON PHARMACEUTICALS, INC. filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Regeneron Pharmaceuticals (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.